Drug metabolism in human BJ cells assessed as ADK-mediated 4-(Methylsulfanyl)-8-(beta-D-ribofuranosyl)-8H-thieno[2, 3:4,5]-pyrrolo[2,3-d]pyrimidine-5-O-monophosphate Sodium Salt formation per 5 x10'5 cells at 1 umol/L after 1 hr by UPLC-MS/MS analysis
Drug metabolism in human HCT116 cells assessed as ADK-mediated 4-(Methylsulfanyl)-8-(beta-D-ribofuranosyl)-8H-thieno[2, 3:4,5]-pyrrolo[2,3-d]pyrimidine-5-O-monophosphate Sodium Salt formation per 5 x10'5 cells at 1 umol/L after 1 hr by UPLC-MS/MS analysis
Drug metabolism in human BJ cells assessed as ADK-mediated 4-(Methylsulfanyl)-8-(beta-D-ribofuranosyl)-8H-thieno[2, 3:4,5]-pyrrolo[2,3-d]pyrimidine-5-O-monophosphate Sodium Salt formation per 5 x10'5 cells at 1 umol/L after 3 hrs by UPLC-MS/MS analysis
Drug metabolism in human HCT116 cells assessed as ADK-mediated 4-(Methylsulfanyl)-8-(beta-D-ribofuranosyl)-8H-thieno[2, 3:4,5]-pyrrolo[2,3-d]pyrimidine-5-O-monophosphate Sodium Salt formation per 5 x10'5 cells at 1 umol/L after 3 hrs by UPLC-MS/MS analysis
Drug metabolism in human BJ cells assessed as ADK-mediated 4-(Methylsulfanyl)-8-(beta-D-ribofuranosyl)-8H-thieno[2, 3:4,5]-pyrrolo[2,3-d]pyrimidine-5-O-monophosphate Sodium Salt formation per 5 x10'5 cells at 10 umol/L after 1 hr by UPLC-MS/MS analysis
Drug metabolism in human HCT116 cells assessed as ADK-mediated 4-(Methylsulfanyl)-8-(beta-D-ribofuranosyl)-8H-thieno[2, 3:4,5]-pyrrolo[2,3-d]pyrimidine-5-O-monophosphate Sodium Salt formation per 5 x10'5 cells at 10 umol/L after 1 hr by UPLC-MS/MS analysis
Drug metabolism in human BJ cells assessed as ADK-mediated 4-(Methylsulfanyl)-8-(beta-D-ribofuranosyl)-8H-thieno[2, 3:4,5]-pyrrolo[2,3-d]pyrimidine-5-O-monophosphate Sodium Salt formation per 5 x10'5 cells at 10 umol/L after 3 hrs by UPLC-MS/MS analysis